A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R (Canocapavir) in Combination With Nucleos(t)Ide Analog(NAs) Compared With NAs Monotherapy in Patients With Chronic Hepatitis B Who Have Received NAs Monotherapy for at Least 12 Months

This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.

Start Date01 Aug 2025

Sponsor / Collaborator

Shanghai Zhimeng Biopharma, Inc.

NCT06990776

/ WithdrawnPhase 2

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive HBeAg-positive Subjects With Chronic HBV Infection

This is a multicenter, randomized, double-blind, placebo-controlled phase II study, in which all participants are required to use TQA3605 tablets/placebo in combination with entecavir. The purpose is to evaluate the efficacy and safety of TQA3605 tablets combined with entecavir in treatment-naive chronic HBV-infected subjects. A total of 215 subjects are required.

Start Date09 Jul 2025

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

CTRI/2025/03/082856

/ Not yet recruitingPhase 3IIT

Multicentric, open label, pragmatic, randomized, controlled trial to compare the clinical outcome with 0.5 versus 1.0 mg entecavir for hepatitis B related decompensated cirrhosis - SECOND trial (Single dose of Entecavir for COmpensated and Decompensated cirrhosis- a Noninferiority trial)

Start Date01 Jul 2025

Sponsor / Collaborator

Indian Council of Medical Research

100 Clinical Results associated with Entecavir

100 Translational Medicine associated with Entecavir

100 Patents (Medical) associated with Entecavir

4,384

Literatures (Medical) associated with Entecavir

31 Dec 2025·Emerging Microbes & Infections

High HBsAg clearance rate and viral dynamics in HBeAg-positive, ALT-normal children and adolescents with chronic HBV infection: results from the prospective sprout project

Article

Author: Tang, Qiyuan ; Wang, Xin ; Zhang, Zheng ; Lei, Jia ; Li, Ruiling ; Lai, Changxiang ; Li, Zhiyu ; Xie, Yuyin ; He, Qing ; Wang, Fang ; Zhang, Hongfei

Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection in children and adolescents with normal alanine aminotransferase (ALT) levels constitutes a substantial population in China, yet the optimal timing for antiviral therapy remains unclear. This prospective, real-world study, conducted as the primary centre of the Sprout Project, evaluated the hepatitis B surface antigen (HBsAg) loss rate and viral-immune dynamics of pegylated interferon α (PEG-IFN-α) treatment in 85 chronic HBV patients aged 3-18 years over a 24-month period. A total of 27 HBeAg-positive, ALT-normal patients were selected for analysis. Patients were treated with a combination of PEG-IFN-α and entecavir. After 24 months, the overall HBsAg loss rate was 48.15%, with 47.37% in the immune-tolerant phase and 50% in the grey zone phase. Among those who cleared HBsAg, 84.62% had ALT elevation prior to anti-HBsAg antibody (HBsAb) seroconversion, which occurred 28-400 days before HBsAg loss. While HBsAg and HBV DNA were cleared by 24 months in the HBsAg loss group, 23.08% of children remained HBeAg-positive. Notably, 61.54% developed detectable HBsAb prior to HBsAg loss. Children aged 3-7 years had significantly higher clearance rates than those aged 8-18 years. These findings support the effectiveness of PEG-IFN-α combined with nucleos(t)ide analogs in achieving high HBsAg loss rates in young, HBeAg-positive, ALT-normal chronic HBV children and adolescents, with immune activation potentially preceding ALT elevation, and offers valuable insights into the viral-immune dynamics during treatment, highlighting the potential of antiviral therapy in this population.

01 Dec 2025·CHILDS NERVOUS SYSTEM

Comparison of postoperative outcomes following endoscopic third ventriculostomy or shunt in a propensity score matched pediatric cohort

Article

Author: Piatt, Joseph ; Castro, Paulo ; Berman, Loren

Abstract:

Purpose:

Thirty-day readmission and reoperation are widely used quality metrics. Endoscopic third ventriculostomy (ETV) is favored when feasible, but may compare unfavorably with shunt in the short-term. This study analyzes 30-day outcomes of ETV and shunt surgery in comparable populations.

Methods:

Data regarding patients undergoing ETV or initial shunt insertion were extracted from the National Surgical Quality Improvement Program – Pediatric for 2013–2020. Patients were stratified into three age groups: ≤ 6 months (N = 5,906), 6 months-2 years (N = 2,364), and ≥ 2 years (N = 4,408). Characteristics were compared before and after propensity-score matching. Outcome comparisons included CNS complications, mortality, readmission, and reinterventions.

Results:

There were 10,135 shunt insertions and 2,543 ETVs. After matching, patients ≤ 6 months undergoing ETV had more seizures (ETV 6.3% vs shunt 0.4%, p < 0.001), readmission (ETV 15.7% vs shunt 6.1%, p < 0.001), and reintervention (ETV 17.4% vs shunt 4.8%, p < 0.001). Among patients 6 months—2 years, ETV increased seizures (ETV 3.3% vs shunt 1.0%, p = 0.01), readmission (ETV 14.9% vs shunt 7.8%, p < 0.001), and reintervention (ETV 13.0% vs shunt 5.4%, p < 0.001). Among older patients, ETV had decreased median length of stay (ETV 3 days, IQR 1–6 days vs shunt 3 days, IQR 2–8 days, p = 0.0019) and mortality (ETV 0.4% vs shunt 1.5%, p = 0.007).

Conclusion:

Outcomes following shunt surgery and ETV in matched patients appear to be age-dependent. Younger patients undergoing ETV encountered more short-term complications. 30-day outcomes may be misleading as a quality measure in the management of childhood hydrocephalus.

01 Dec 2025·CHILDS NERVOUS SYSTEM

Clinical and radiologic criteria to predict endoscopic third ventriculostomy success in non-communicating pediatric hydrocephalus

Article

Author: Pennacchietti, Valentina ; Thomale, Ulrich-W ; Tietze, Anna ; Cohrs, Gesa ; Schaumann, Andreas ; Tatoshvili, Davit ; Schulz, Matthias

Abstract:

Objective:

Endoscopic third ventriculocisternostomy (ETV) became the relevant treatment option for non-communicating pediatric hydrocephalus. ETV success was predicted in relation to age, diagnosis, and previous shunt implantation. Radiological factors are usually taken for indication decision-making. The aim of this study is to investigate radiological signs of non-communicating hydrocephalus for ETV success in a single-center retrospective analysis.

Patients and methods:

ETV interventions were collected from a 10-year period (2010–2019) from our institution. Clinical patient characteristics such as prematurity, age, diagnosis, and previous shunt treatment and follow-up in terms of possible shunt implantation or revision surgeries were investigated. Radiological data was retrieved from the in-house PACS system to analyze preoperative signs for noncommunicating hydrocephalus such as ventricular size, pressure gradients at the third ventricle, and any signs of obstruction from internal towards external cerebral spinal fluid communication. Fisher’s test was used to demonstrate the significance of each individual predictor. A multivariable model was built using the backward elimination method with multiple logistic regression.

Results:

From 136 ETV interventions, 95 met the inclusion criteria (age < 18 years; > 6-month follow-up; MR image data availability, treatment goal for shunt independence). In chi-square statistical evaluation of single parameters age > 6 months (OR 32.5; 95% CI 4.8–364), ventricular width (FOHR < 0.56; OR 6.1; 95% CI 2.2–16.3) and non-post-hemorrhagic hydrocephalus as underlying diagnosis (OR 13.1; 95% CI 1.9–163) showed significant increased odds ratio for shunt independence during follow-up. Logistic regression analysis for multiple parameters showed age > 6 months (OR 29.3; 95% CI 4.1–606) together with outward bulged lamina terminalis (OR 4.6; 95% CI 1.2–19.6), smaller FOHR (continuous parameter; OR 2.83 × 10−5; 95% CI 4.7 × 10−9–0.045), and non-4th-ventricular-outlet obstruction (4thVOO; OR 0.31; 95% CI 0.09–1.02) as significant factors for ETV success.

Conclusion:

ETV has become a relevant treatment for non-communicating hydrocephalus, with typical MR image characteristics. Analyzing radiological markers as predictors for success smaller ventricular width and outward displaced lamina terminalis was relevant in combination with age > 6 months. Since the analysis is based on single-center experience, a larger cohort of patients with a multi-center approach should further investigate the combined clinical and radiological criteria.

News (Medical) associated with Entecavir

13 Aug 2025

·pipelinereview.com

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, CA, USA I August 13, 2025 I Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection. “Despite available treatments for chronic HBV infection, better therapies are needed to stem the progression to end-stage liver disease and liver cancer,” said Nezam Afdhal, MD, DSc, Chief of Gastroenterology, Hepatology, and Nutrition at Beth Israel Deaconess Medical Center and Charlotte & Irving Rabb Distinguished Professor of Medicine at Harvard Medical School. “I am pleased that therapies such as Aligos’ ALG-000184 are continuing to progress. The impressive antiviral activity seen in clinical trials to date provides hope for patients in need.” “Dosing the first subjects in our Phase 2 B-SUPREME study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “We are pleased by the engagement of the clinicians and subjects, as they recognize the need for improved treatment regimens for chronic HBV infection. We believe that ALG-000184 has first/best-in-class potential based on the exciting data seen across viral markers of HBV to date. We look forward to continuing to advance ALG-000184 for patients in need of better outcomes.” The Phase 2 B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg + and HBeAg – adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg + part will be HBV DNA

Phase 2Phase 1Clinical ResultVaccine

13 Aug 2025

·investor.aligos.com

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection. “Despite available treatments for chronic HBV infection, better therapies are needed to stem the progression to end-stage liver disease and liver cancer,” said Nezam Afdhal, MD, DSc, Chief of Gastroenterology, Hepatology, and Nutrition at Beth Israel Deaconess Medical Center and Charlotte & Irving Rabb Distinguished Professor of Medicine at Harvard Medical School. “I am pleased that therapies such as Aligos’ ALG-000184 are continuing to progress. The impressive antiviral activity seen in clinical trials to date provides hope for patients in need.” “Dosing the first subjects in our Phase 2 B-SUPREME study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “We are pleased by the engagement of the clinicians and subjects, as they recognize the need for improved treatment regimens for chronic HBV infection. We believe that ALG-000184 has first/best-in-class potential based on the exciting data seen across viral markers of HBV to date. We look forward to continuing to advance ALG-000184 for patients in need of better outcomes.” The Phase 2 B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg+ and HBeAg- adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg+ part will be HBV DNA

Phase 2Phase 1Clinical ResultVaccine

08 May 2025

·www.einpresswire.com

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. “We are pleased to have eight presentations at this year’s EASL Congress from programs across our pipeline,” stated Lawrence Blatt, PhD, MBA, Chairman, President, & CEO of Aligos Therapeutics. “In particular, we are excited to share an update on the 96-week data from the monotherapy cohort receiving 300 mg ALG-000184. All subjects in both the HBeAg + and HBeAg - cohorts have achieved HBV DNA viral suppression < LLOQ (10 IU/mL) and continue to demonstrate sustained log 10 reductions in viral antigens such as HBcrAg. These data further strengthen our belief that ALG-000184 is a first-/best-in-class asset with the potential to improve patient outcomes. Additionally, we will present biomarker and subgroup analyses from the Phase 2a HERALD study. These data continue to demonstrate the best-in-class potential of ALG-055009 across the cardio-metabolic space.” Two presentations highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B virus (HBV) infection in both untreated HBeAg + and HBeAg - subjects, demonstrating the potential for the molecule to become first-line therapy for chronic suppression and the backbone for regimens aimed at functional cure. In HBeAg + subjects with a very high mean HBV DNA level of 8.0 log 10 IU/mL at baseline, all experienced profound and persistent HBV DNA reductions after receiving an oral daily dose of 300 mg ALG-000184 monotherapy. At Week 48, 6 of 10 subjects (60%) achieved HBV DNA < LLOQ (10 IU/mL, target detected or target not detected). With treatment extension, this rate increased to 9 of 9 subjects (100%) at Week 96. Additionally, HBV DNA level continuously declined to < LLOQ (target not detected, <4.29 IU/mL) in 5 of 9 subjects at Week 96. In HBeAg - subjects, all 11 (100%) had rapid decline in HBV DNA levels and achieved sustained HBV DNA suppression (HBV DNA < LLOQ, target detected or target not detected) by Week 24. The HBV DNA suppression level was maintained in the ALG-000184 monotherapy cohort for up to 96 weeks, with further decline in HBV DNA to < LLOQ, target not detected, observed in all subjects (8/8) at Week 96. Importantly, no viral breakthrough was observed in any chronic HBV infection subjects receiving ALG-000184 monotherapy for up to 96 weeks. The resistant analysis reported no known CAM resistant mutations had been identified with ALG-000184 monotherapy. HBV RNA level achieved < LLOQ (10 copies/mL) in all HBeAg + and HBeAg - subjects by Week 52 and Week 8, respectively. Furthermore, concurrent multi-log 10 reductions in HBV antigens (HBsAg, HBeAg, and HBcrAg) in HBeAg + subjects and HBcrAg decline in HBeAg - subjects were observed, suggesting the potential inhibition of cccDNA establishment by CAM-E 2 nd mechanism of action of ALG-000184. A favorable tolerability profile has been demonstrated in untreated HBeAg + and HBeAg - subjects receiving 300 mg ALG-000184 for up to 96 weeks. Additionally, two presentations will showcase the best-in-class potential of ALG-055009, a purpose built THR-β agonist discovered by Aligos scientists. As previously presented at AASLD’s The Liver Meeting in 2024, 12-weeks of once daily ALG-055009 treatment in MASH patients met the primary endpoint, with robust reductions in liver fat content at Week 12. Doses of 0.5 mg to 0.9 mg ALG-055009 demonstrated statistically significant reductions in liver fat at Week 12, with placebo-adjusted median relative reductions up to 46.2% as measured by MRI-PDFF. Eighteen subjects who were on stable GLP-1 agonist therapy qualified for enrollment in the study, with liver fat content meeting the inclusion criteria of ≥10% at baseline as measured by MRI-PDFF. Notably, 11/14 subjects on stable GLP-1 agonists treated with ALG-055009 had liver fat decreases, whereas 4/4 subjects on stable GLP-1 agonists treated with placebo had increases in liver fat over the 12-week dosing period. Treatment with ALG-055009 was well-tolerated, with rates of gastrointestinal-related AEs similar to placebo. New data being presented at the EASL congress will demonstrate substantial, dose-dependent reductions in liver fat were observed across all key subgroups with 12 weeks of once daily ALG-055009 treatment. In addition, statistically significant improvements in atherogenic lipids were achieved with 12 weeks of ALG-055009 treatment. Reductions in lipids/lipoproteins were observed even in the context of stable GLP-1 agonist or statin use. This data suggests an added benefit of ALG-055009 for patients at risk for cardiovascular disease in addition to the previously reported liver fat lowering properties in a MASLD/MASH population. Details of the presentations are as follows: ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection Poster #: THU-261 Title: Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV Infection Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong Date/Time: May 8, 2025 at 4:15pm – 5:00pm CET; May 8, 2025 at 8:30am – 5:00pm CET Session: Poster Tour; Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Poster #: THU-256 Title: The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection Presenter: Professor Jinlin Hou, MD, Chairman and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University Date/Time: May 8, 2025 at 8:30am – 5:00pm CET Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Poster #: THU-242 Title: Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184 Presenter: Andreas Jekle, PhD Date/Time: May 8, 2025 at 8:30am – 5:00pm CET Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies ALG-055009: Potential best-in-class small molecule THR- β for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Poster #: SAT-451 Title: ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD Presenter: Stanley Wang, MD, PhD Date/Time: May 8, 2025 at 9:45am – 10:30am CET; May 10, 2025 at 8:30am – 4:00pm CET Sessions: Poster tour; Poster - MASLD: Therapy Poster #: SAT-450 Title: ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study Presenter: Megan Fitzgerald, PhD Date/Time: May 10, 2025 at 8:30am – 4:00pm CET Session: Poster - MASLD: Therapy Poster #: SAT-430 Title: Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints Presenter: Kha Le, PhD Date/Time: May 10, 2025 at 8:30am – 4:00pm CET Session: Poster - MASLD: Therapy Poster #: FRI-450 Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice Presenter: Xuan Luong, PhD Date/Time: May 9, 2025 at 8:30am – 5:00pm CET Session: Poster - MASLD: Experimental and pathophysiology Preclinical Poster #: FRI-257 Title: Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidate s Presenter: Jin Hong, PhD Date/Time: May 9, 2025 at 8:30am – 5:00pm CET Session: Poster - Viral Hepatitis: Experimental and pathophysiology About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Investor Contact Aligos Therapeutics, Inc. Jordyn Tarazi Vice President, Investor Relations & Corporate Communications +1 (650) 910-0427 jtarazi@aligos.com Media Contact Inizio Evoke Jake Robison Vice President Jake.Robison@inizioevoke.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultPhase 2Phase 1

100 Deals associated with Entecavir

External Link

KEGG	Wiki	ATC	Drug Bank
D04008	Entecavir	J05AF10	DB00442

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B, Chronic	United States	Bristol Myers Squibb Co.	29 Mar 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Disease	Phase 3	United States	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Canada	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Hong Kong	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Indonesia	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Philippines	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Singapore	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Taiwan Province	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Thailand	Bristol Myers Squibb Co.	01 Dec 2004
Hepatitis B	Phase 3	United States	Bristol Myers Squibb Co.	01 Sep 2002
Viremia	Phase 3	United States	Bristol Myers Squibb Co.	01 Sep 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04536337 (ALG-000184-201, EASL2024) Manual	Phase 1	Hepatitis B, Chronic	22	ALG-000184 + ETV	vzcrosgjan(dsnagjqmsu) = In a multiple regression model, baseline HBsAg (< or ≥4 log10 IU/ ml) and steady state plasma ALG-001075 exposure (AUC or Ctrough) statistically significantly predicted change from baseline in HBsAg at week 24 (p < 0.00018, R2 = 0.65). fqvhkzgsjy (rftaiduaae ) View more	Positive	01 Jun 2024
				ALG-000184
NCT04536337 (ALG-000184-201, EASL2024) Manual	Phase 1	Hepatitis B, Chronic	22	ALG-000184 + Entecavir	mbfsmvuerb(mikfgzrfih) = wiygyhqvvv graesacuqk (uvanhjwobj, 0.4) View more	Positive	01 Jun 2024
				ALG-000184	-
NCT03887702 (CTgov)	Phase 3	Hepatitis B \| Malignant Solid Neoplasm	4	Tenofovir Alafenamide+Tenofovir Disoproxil Fumarate+Entecavir (Arm 1 (TAF, TDF, Entecavir: Prophylactic))	pinraozdij(vudrfxaruf) = kkodypfvcx ywkewihxos (abhblnppcs, yekxcjgfdg - mqrjrbgxdq) View more	-	20 May 2024
				Tenofovir Alafenamide+Tenofovir Disoproxil Fumarate+Entecavir (Arm 2 (TAF, TDF, Entecavir: Upon Indication))	pinraozdij(vudrfxaruf) = zvskhyrcds ywkewihxos (abhblnppcs, vxecinyguw - bjllrzjrqs) View more
NCT03083821 (CTgov)	Phase 1	Hepatitis B, Chronic \| Hepatitis B	6	Baraclude	bczolntypg(xqvndaoxph) = vpkaktffdf ehjaoihghd (rbncemuexj, 2.517) View more	-	18 Nov 2023
AASLD2023	Not Applicable	Decompensated cirrhosis of liver	283	Entecavir	rtvgbtyedx(kxyjyxjzvi) = pncqnfyjzk fhsjrlufno (pygfykudct ) View more	-	10 Nov 2023
				Entecavir	rtvgbtyedx(kxyjyxjzvi) = icinahgcnz fhsjrlufno (pygfykudct ) View more
AASLD2023	Not Applicable	Hepatitis B	194	Entecavir	bkckwdlehb(tuctjjxpwo) = ocowppzvcz eaeagaabkq (ckorbqisol, 18.0 - 31.0) View more	-	10 Nov 2023
NCT04781647 (CTgov)	Phase 2	Hepatitis B, Chronic	54	ETV+ABI-H0731 (ABI-H0731 + ETV)	yijpwmbhey = wuypqrnqkw plmicskkwr (sunxarcehy, xrhenefsdy - ogwjgjnxnz) View more	-	06 Oct 2023
				Peg-IFNα+ETV+ABI-H0731 (ABI-H0731 + ETV + Peg-IFNα)	yijpwmbhey = pzxzzxaxwe plmicskkwr (sunxarcehy, spvesabsid - watfdmorpf) View more
ChiCTR-IPR-17012055 (Pubmed \| Aliment Pharmacol Ther)	Phase 4	Hepatitis B, Chronic Add-on	153	Add-on PEG-IFN	ldstibbvyw(yruiliiebu) = rwuxapqqqm ktmwynvifs (qecmldaldx ) View more	-	20 Sep 2022
				Switch-to PEG-IFN	ldstibbvyw(yruiliiebu) = gcnrjoqjqv ktmwynvifs (qecmldaldx ) View more
NCT03577171 (Pubmed)	Phase 2	Hepatitis B, Chronic	25	Vebicorvir 300 mg+Entecavir 0.5 mg	vneqcvthaz(uazhmfxmgi) = cxrrtckosd crcnqhxnzb (zgacbcfxph ) View more	-	10 Jun 2022
				Placebo+Entecavir 0.5 mg	vneqcvthaz(uazhmfxmgi) = uayvdsnpfw crcnqhxnzb (zgacbcfxph ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis